NO20010982L - Fremgangsmåte for å administrere insulinotropiske peptider - Google Patents

Fremgangsmåte for å administrere insulinotropiske peptider

Info

Publication number
NO20010982L
NO20010982L NO20010982A NO20010982A NO20010982L NO 20010982 L NO20010982 L NO 20010982L NO 20010982 A NO20010982 A NO 20010982A NO 20010982 A NO20010982 A NO 20010982A NO 20010982 L NO20010982 L NO 20010982L
Authority
NO
Norway
Prior art keywords
administering
insulinotropic peptides
inhalation
peptide
molecules
Prior art date
Application number
NO20010982A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010982D0 (no
Inventor
Benjamin Lee Hughes
Ronald Keith Wolff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20010982(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20010982D0 publication Critical patent/NO20010982D0/no
Publication of NO20010982L publication Critical patent/NO20010982L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO20010982A 1998-08-28 2001-02-27 Fremgangsmåte for å administrere insulinotropiske peptider NO20010982L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9827398P 1998-08-28 1998-08-28
US10001298P 1998-09-11 1998-09-11
PCT/US1999/019348 WO2000012116A1 (fr) 1998-08-28 1999-08-24 Procede pour administrer des peptides insulinotropiques

Publications (2)

Publication Number Publication Date
NO20010982D0 NO20010982D0 (no) 2001-02-27
NO20010982L true NO20010982L (no) 2001-04-27

Family

ID=26794577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010982A NO20010982L (no) 1998-08-28 2001-02-27 Fremgangsmåte for å administrere insulinotropiske peptider

Country Status (21)

Country Link
EP (1) EP0997151B1 (fr)
JP (1) JP2002523466A (fr)
KR (1) KR20010073033A (fr)
CN (1) CN1314818A (fr)
AR (1) AR022368A1 (fr)
AT (1) ATE347902T1 (fr)
AU (1) AU764371B2 (fr)
BR (1) BR9913284A (fr)
CA (1) CA2341454A1 (fr)
CO (1) CO5090908A1 (fr)
CZ (1) CZ2001690A3 (fr)
DE (1) DE69934380D1 (fr)
EA (1) EA200100289A1 (fr)
HR (1) HRP20010141A2 (fr)
HU (1) HUP0103369A3 (fr)
IL (1) IL141241A0 (fr)
NO (1) NO20010982L (fr)
PE (1) PE20001031A1 (fr)
PL (1) PL346317A1 (fr)
TR (1) TR200100600T2 (fr)
WO (1) WO2000012116A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
WO2001093837A2 (fr) * 2000-06-08 2001-12-13 Eli Lilly And Company Poudre proteinique administree par voie pulmonaire
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2002308706A1 (en) * 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
HUP0700151A2 (en) * 2001-10-18 2007-05-29 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
WO2003080149A2 (fr) 2002-03-20 2003-10-02 Mannkind Corporation Appareil d'inhalation
EP2409686A1 (fr) * 2002-08-01 2012-01-25 Mannkind Corporation Compositions de transport cellulaire et utilisations
EP1594530A4 (fr) 2003-01-22 2006-10-11 Human Genome Sciences Inc Proteines hybrides d'albumine
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
AU2004298424A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 compounds
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
KR100704447B1 (ko) * 2005-05-16 2007-04-09 정용현 3단계로 코팅되는 김치 유산균의 코팅방법 및 그로부터 제조된 코팅된 김치유산균 및 코팅된 김치 유산균이 함유된 조성물
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
JP2009514900A (ja) * 2005-11-04 2009-04-09 スミスクライン・ビーチャム・コーポレイション 血糖降下剤の投与方法
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
PE20121528A1 (es) * 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CN101969927A (zh) * 2007-10-24 2011-02-09 曼金德公司 预防glp-1不良影响的方法
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX2010014240A (es) 2008-06-20 2011-03-25 Mankind Corp Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
MX2011007371A (es) 2009-01-08 2011-09-06 Mannkind Corp Metodo para tratar la hiperglucemia con la molecula.
WO2010105094A1 (fr) 2009-03-11 2010-09-16 Mannkind Corporation Appareil, système et procédé de mesure de résistance d'un inhalateur
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (fr) 2009-11-03 2011-05-12 Mannkind Corporation Appareil et méthode de simulation d'efforts d'inhalation
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (fr) 2011-06-17 2012-12-20 Mannkind Corporation Microparticules de dicétopipérazine de capacité élevée
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
WO2014066856A1 (fr) 2012-10-26 2014-05-01 Mannkind Corporation Compositions et procédés de vaccin antigrippal inhalable
KR102246914B1 (ko) 2013-03-15 2021-04-30 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
CN114848614A (zh) 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
EP3030294B1 (fr) 2013-08-05 2020-10-07 MannKind Corporation Appareil d'insufflation
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11359267B2 (en) 2017-02-21 2022-06-14 Jfe Steel Corporation High-carbon hot-rolled steel sheet and method for manufacturing the same
GB201917723D0 (en) 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
KR20250152464A (ko) 2024-04-16 2025-10-23 한미약품 주식회사 흡입제 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
IL128332A0 (en) * 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
TR200001021T2 (tr) * 1997-07-18 2000-09-21 Infimed Inc. Aktif maddelerin kontrollü salınması için biyo aşındırılabilir makromerler.

Also Published As

Publication number Publication date
EA200100289A1 (ru) 2001-10-22
HUP0103369A3 (en) 2002-03-28
CN1314818A (zh) 2001-09-26
JP2002523466A (ja) 2002-07-30
ATE347902T1 (de) 2007-01-15
AR022368A1 (es) 2002-09-04
IL141241A0 (en) 2002-03-10
DE69934380D1 (de) 2007-01-25
EP0997151A3 (fr) 2000-09-20
PE20001031A1 (es) 2000-10-12
WO2000012116A1 (fr) 2000-03-09
HUP0103369A2 (hu) 2002-02-28
TR200100600T2 (tr) 2001-07-23
BR9913284A (pt) 2001-05-15
CO5090908A1 (es) 2001-10-30
AU764371B2 (en) 2003-08-14
KR20010073033A (ko) 2001-07-31
HRP20010141A2 (en) 2002-02-28
NO20010982D0 (no) 2001-02-27
AU5584199A (en) 2000-03-21
CA2341454A1 (fr) 2000-03-09
PL346317A1 (en) 2002-01-28
EP0997151A2 (fr) 2000-05-03
CZ2001690A3 (cs) 2002-04-17
EP0997151B1 (fr) 2006-12-13

Similar Documents

Publication Publication Date Title
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
WO2003061362A3 (fr) Procedes et compositions pour le traitement du syndrome des ovaires polykystiques
NO20003051L (no) Metode for administrering av AspB28-humant insulin
MY134820A (en) Glucagon-like insulinotropic complexes, compositions and methods
WO2006024275A3 (fr) Invention concernant le glp-1 et l'exendine
EA200300026A1 (ru) Аналоги глюкагоноподобного пептида-1
IL176541A0 (en) Intranasal administration of glucose-regulating peptides
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
DK1409006T3 (da) Monodispergerede blandinger og fremgangsmåder til behandling af diabetes
DE68929217D1 (en) Insulinotropes hormon
WO2003053339A3 (fr) Molecule d'insuline a duree d'action prolongee
WO2004056313A3 (fr) Prevention et traitement d'arythmies cardiaques
NO20015932L (no) Fremgangsmåte til å behandle diabetes
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos
UA88862C2 (en) Glucagon-like peptide-1 analogs

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application